耐抗生素的 ESKAPE 病原体与 COVID-19：大流行之外的大流行。
Antibiotic-Resistant ESKAPE Pathogens and COVID-19: The Pandemic beyond the Pandemic.
机构信息
Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Via Orabona 4, 70126 Bari, Italy.
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy.
出版信息
Viruses. 2023 Aug 30;15(9):1843. doi: 10.3390/v15091843.
Abstract
Antibacterial resistance is a renewed public health plague in modern times, and the COVID-19 pandemic has rekindled this problem. Changes in antibiotic prescribing behavior, misinformation, financial hardship, environmental impact, and governance gaps have generally enhanced the misuse and improper access to antibiotics during the COVID-19 pandemic. These determinants, intersected with antibacterial resistance in the current pandemic, may amplify the potential for a future antibacterial resistance pandemic. The occurrence of infections with multidrug-resistant (MDR), extensively drug-resistant (XDR), difficult-to-treat drug-resistant (DTR), carbapenem-resistant (CR), and pan-drug-resistant (PDR) bacteria is still increasing. The aim of this review is to highlight the state of the art of antibacterial resistance worldwide, focusing on the most important pathogens, namely , , and , and their resistance to the most common antibiotics.
摘要
抗菌耐药性是现代社会新出现的公共卫生瘟疫，而 COVID-19 大流行又重新引发了这一问题。抗生素处方行为的改变、错误信息、经济困难、环境影响以及治理差距等因素普遍加剧了 COVID-19 大流行期间抗生素的滥用和不当使用。这些决定因素与当前大流行中的抗菌耐药性相互交织，可能会放大未来抗菌耐药性大流行的潜在风险。具有多重耐药性（MDR）、广泛耐药性（XDR）、难以治疗耐药性（DTR）、碳青霉烯耐药性（CR）和全耐药性（PDR）的细菌感染仍在不断增加。本综述的目的是强调全球抗菌耐药性的最新进展，重点关注最重要的病原体，即 、 、 和 ，以及它们对最常见抗生素的耐药性。
相似文献
1
Antibiotic-Resistant ESKAPE Pathogens and COVID-19: The Pandemic beyond the Pandemic.
Viruses. 2023 Aug 30;15(9):1843. doi: 10.3390/v15091843.
2
Importance of control groups when delineating antibiotic use as a risk factor for carbapenem resistance, extreme-drug resistance, and pan-drug resistance in Acinetobacter baumannii and Pseudomonas aeruginosa: A systematic review and meta-analysis.
Int J Infect Dis. 2018 Nov;76:48-57. doi: 10.1016/j.ijid.2018.05.017. Epub 2018 Jun 2.
3
Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii Pulmonary Infection.
mBio. 2022 Feb 22;13(1):e0351721. doi: 10.1128/mbio.03517-21. Epub 2022 Jan 11.
4
Meropenem in combination with baicalein exhibits synergism against extensively drug resistant and pan-drug-resistant Acinetobacter baumannii clinical isolates in vitro.
Pathog Dis. 2023 Jan 17;81. doi: 10.1093/femspd/ftad007.
5
Impact of coronavirus disease 2019 (COVID-19) on antimicrobial resistance among major pathogens causing healthcare-associated infection.
J Formos Med Assoc. 2024 Jan;123(1):123-132. doi: 10.1016/j.jfma.2023.06.026. Epub 2023 Jul 12.
6
Epidemiology of community origin of major multidrug-resistant ESKAPE uropathogens in a paediatric population in South-East Gabon.
Antimicrob Resist Infect Control. 2023 May 12;12(1):47. doi: 10.1186/s13756-023-01250-y.
7
Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of Acinetobacter baumannii.
Phytomedicine. 2017 Jan 15;24:49-55. doi: 10.1016/j.phymed.2016.11.007. Epub 2016 Nov 17.
8
Gram-negative ESKAPE bacteria bloodstream infections in patients during the COVID-19 pandemic.
PeerJ. 2023 Mar 29;11:e15007. doi: 10.7717/peerj.15007. eCollection 2023.
9
Carbapenemase-Encoding Genes and Colistin Resistance in Gram-Negative Bacteria During the COVID-19 Pandemic in Mexico: Results from the Invifar Network.
Microb Drug Resist. 2023 Jun;29(6):239-248. doi: 10.1089/mdr.2022.0226. Epub 2022 Dec 30.
10
Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Expert Rev Anti Infect Ther. 2023 Apr;21(4):387-429. doi: 10.1080/14787210.2023.2184346. Epub 2023 Mar 8.
引用本文的文献
1
Nicotianin-I: A Tobacco Floral Nectar Peptide with Anticandidal Activity.
ACS Omega. 2025 May 14;10(20):20213-20225. doi: 10.1021/acsomega.4c10806. eCollection 2025 May 27.
2
Development of Inhalable Bacteriophage Liposomes Against .
Pharmaceutics. 2025 Mar 24;17(4):405. doi: 10.3390/pharmaceutics17040405.
3
Performance and hypothetical clinical impact of an mNGS-based machine learning model for antimicrobial susceptibility prediction of five ESKAPEE bacteria.
Microbiol Spectr. 2025 Jun 3;13(6):e0259224. doi: 10.1128/spectrum.02592-24. Epub 2025 Apr 17.
4
Antimicrobial Resistance in ESKAPE Pathogens: A Retrospective Epidemiological Study at the University Hospital of Palermo, Italy.
Antibiotics (Basel). 2025 Feb 12;14(2):186. doi: 10.3390/antibiotics14020186.
5
Silver -Heterocyclic Carbene (NHC) Complexes as Antimicrobial and/or Anticancer Agents.
Pharmaceuticals (Basel). 2024 Dec 25;18(1):9. doi: 10.3390/ph18010009.
6
Chitosan-Based Schiff Bases (CSBs) and Their Metal Complexes: Promising Antimicrobial Agents.
Molecules. 2025 Jan 7;30(2):207. doi: 10.3390/molecules30020207.
7
Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.
Antibiotics (Basel). 2025 Jan 9;14(1):63. doi: 10.3390/antibiotics14010063.
8
Bacterial Infections, Trends, and Resistance Patterns in the Time of the COVID-19 Pandemic in Romania-A Systematic Review.
Antibiotics (Basel). 2024 Dec 14;13(12):1219. doi: 10.3390/antibiotics13121219.
9
"One Health" Perspective on Prevalence of ESKAPE Pathogens in Africa: A Systematic Review and Meta-Analysis.
Pathogens. 2024 Sep 12;13(9):787. doi: 10.3390/pathogens13090787.
10
Farnesol Emulsion as an Effective Broad-Spectrum Agent against ESKAPE Biofilms.
Antibiotics (Basel). 2024 Aug 17;13(8):778. doi: 10.3390/antibiotics13080778.
本文引用的文献
1
The Challenge of Overcoming Antibiotic Resistance in Carbapenem-Resistant Gram-Negative Bacteria: "Attack on Titan".
Microorganisms. 2023 Jul 27;11(8):1912. doi: 10.3390/microorganisms11081912.
2
Exploring Synergistic Combinations in Extended and Pan-Drug Resistant (XDR and PDR) Whole Genome Sequenced .
Microorganisms. 2023 May 26;11(6):1409. doi: 10.3390/microorganisms11061409.
3
Identifying and Prioritising Behaviours to Slow Antimicrobial Resistance.
Antibiotics (Basel). 2023 May 23;12(6):949. doi: 10.3390/antibiotics12060949.
4
How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
Lancet Infect Dis. 2023 Aug;23(8):e301-e309. doi: 10.1016/S1473-3099(23)00124-X. Epub 2023 Jun 5.
5
The global antimicrobial resistance response effort must not exclude marginalised populations.
Trop Med Health. 2023 Jun 7;51(1):33. doi: 10.1186/s41182-023-00524-w.
6
Multidrug-resistant gram-negative bacteria in patients with COVID-19: An epidemiological and clinical study.
J Infect Public Health. 2023 Aug;16(8):1184-1192. doi: 10.1016/j.jiph.2023.05.017. Epub 2023 May 17.
7
ESKAPE and Beyond: The Burden of Coinfections in the COVID-19 Pandemic.
Pathogens. 2023 May 22;12(5):743. doi: 10.3390/pathogens12050743.
8
Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections.
Pharmacotherapy. 2023 Jun;43(6):502-513. doi: 10.1002/phar.2802. Epub 2023 May 23.
9
Bacterial Co-Infections and Antimicrobial Resistance in Patients Hospitalized with Suspected or Confirmed COVID-19 Pneumonia in Kazakhstan.
Pathogens. 2023 Feb 23;12(3):370. doi: 10.3390/pathogens12030370.
10
Genomic Comparative Analysis of Two Multi-Drug Resistance (MDR) Clinical Strains Assigned to International Clonal Lineage II Recovered Pre- and Post-COVID-19 Pandemic.
Biology (Basel). 2023 Feb 24;12(3):358. doi: 10.3390/biology12030358.
Zotero 插件